Thor Medical ASA

Thor Medical ASA - Share capital increase in relation to the Private Placement and the PrimaryBid Offering is registered

26.6.2025 14:24:32 CEST | Thor Medical ASA | Total number of voting rights and

capital

Oslo, Norway, 26 June 2025: Reference is made to stock exchange announcement by

Thor Medical ASA (the "Company") on 18 June 2025 regarding the successful

completion of a private placement of a total of 30,000,000 new shares in the

Company raising a total of NOK 75 million in gross proceeds (the "Private

Placement") and a retail offering of a total of 4,577,399 new shares raising a

total of approx. NOK 11.4 million in gross proceeds (the "PrimaryBid Offering").

The share capital increase relating to the Private Placement and the share

capital increase relating to the PrimaryBid Offering is now registered with the

Norwegian Register of Business Enterprises. The Company's share capital is after

the registration NOK 69,797,184 divided into 348,985,920 shares. Each share has

a nominal value of NOK 0.20 and represents one vote in the Company's general

meeting.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the

Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle

emitters, from naturally occurring thorium. Its proprietary production process

requires no irradiation or use of nuclear reactors, and provides reliable,

environmentally friendly, cost-efficient supply of alpha-emitters for the

radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and

listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

ATTACHMENTS

Download announcement as PDF.pdf -

https://kommunikasjon.ntb.no/ir-files/17848634/18581837/6253/Download%20announce

ment%20as%20PDF.pdf

AI Terminal